Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Zynex ( (ZYXI) ) is now available.
On July 2, 2025, Zynex, Inc. announced that Tricare, its largest insurance customer, will continue the temporary suspension of payments. Despite Zynex’s appeal and presentation of evidence to lift the suspension, Tricare has decided to maintain the suspension while conducting further review, impacting Zynex’s operations and financial stability.
The most recent analyst rating on (ZYXI) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Zynex stock, see the ZYXI Stock Forecast page.
Spark’s Take on ZYXI Stock
According to Spark, TipRanks’ AI Analyst, ZYXI is a Neutral.
Zynex’s overall stock score is heavily impacted by its financial difficulties, which are the most significant factor. Despite some technical and strategic positives, the company’s financial health and valuation concerns dominate, requiring critical focus on revenue growth and cost management for improvement.
To see Spark’s full report on ZYXI stock, click here.
More about Zynex
Zynex, Inc., founded in 1996, is a medical technology company that develops, manufactures, and sells non-invasive medical devices for pain management, rehabilitation, and patient monitoring. The company focuses on providing innovative solutions for hospitals, including fluid, sepsis, and laser-based pulse oximetry monitoring systems.
Average Trading Volume: 235,677
Technical Sentiment Signal: Sell
Current Market Cap: $80.44M
See more data about ZYXI stock on TipRanks’ Stock Analysis page.